156 related articles for article (PubMed ID: 26056473)
1. Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis.
Barosi G; Rosti V; Gale RP
Onco Targets Ther; 2015; 8():1091-102. PubMed ID: 26056473
[TBL] [Abstract][Full Text] [Related]
2. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM
Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.
Manduzio P
Ther Clin Risk Manag; 2017; 13():169-177. PubMed ID: 28243106
[TBL] [Abstract][Full Text] [Related]
4. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
Pinilla-Ibarz J; Sweet KL; Corrales-Yepez GM; Komrokji RS
Onco Targets Ther; 2016; 9():4937-57. PubMed ID: 27570458
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain.
Gómez-Casares MT; Hernández-Boluda JC; Jiménez-Velasco A; Martínez-López J; Ferrario MG; Gozalbo I; Gostkorzewicz J; Subirá R
J Health Econ Outcomes Res; 2018; 5(2):162-174. PubMed ID: 35620778
[No Abstract] [Full Text] [Related]
6. Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis.
Tremblay D; King A; Li L; Moshier E; Coltoff A; Koshy A; Kremyanskaya M; Hoffman R; Mauro MJ; Rampal RK; Mascarenhas J
Leuk Lymphoma; 2020 Mar; 61(3):660-667. PubMed ID: 31711337
[TBL] [Abstract][Full Text] [Related]
7. The use of JAK inhibitors for low-risk myelofibrosis.
Alimam S; McLornan D; Harrison C
Expert Rev Hematol; 2015 Oct; 8(5):551-3. PubMed ID: 26343888
[TBL] [Abstract][Full Text] [Related]
8. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.
Mughal TI; Vaddi K; Sarlis NJ; Verstovsek S
Int J Gen Med; 2014; 7():89-101. PubMed ID: 24501543
[TBL] [Abstract][Full Text] [Related]
9. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.
McMullin MF; Harrison CN; Niederwieser D; Demuynck H; Jäkel N; Gopalakrishna P; McQuitty M; Stalbovskaya V; Recher C; Theunissen K; Gisslinger H; Kiladjian JJ; Al-Ali HK
Exp Hematol Oncol; 2015; 4():26. PubMed ID: 26380150
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase inhibitors: jackpot or potluck?
Pavithran K; Pande SB
Oncol Rev; 2012 Mar; 6(1):e13. PubMed ID: 25992203
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
Rosenthal A; Mesa RA
Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.
Harrison C; Vannucchi AM
Ther Adv Hematol; 2012 Dec; 3(6):341-54. PubMed ID: 23606937
[TBL] [Abstract][Full Text] [Related]
13. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.
Vainchenker W; Leroy E; Gilles L; Marty C; Plo I; Constantinescu SN
F1000Res; 2018; 7():82. PubMed ID: 29399328
[TBL] [Abstract][Full Text] [Related]
14. Emerging therapeutic options for myelofibrosis: a Canadian perspective.
Gupta V; Foltz L; Sirhan S; Busque L; Turner AR
Am J Blood Res; 2012; 2(3):170-86. PubMed ID: 23119228
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors.
Fauble V; Leis J; Mesa RA
Leuk Suppl; 2012 May; 1(Suppl 1):S2-7. PubMed ID: 27175229
[TBL] [Abstract][Full Text] [Related]
16. Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.
Davis KL; Côté I; Kaye JA; Mendelson E; Gao H; Perez Ronco J
Adv Hematol; 2015; 2015():848473. PubMed ID: 26635878
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis.
Claudiani S; Mason CC; Milojkovic D; Bianchi A; Pellegrini C; Di Marco A; Fiol CR; Robinson M; Ponnusamy K; Mokretar K; Chowdhury A; Albert M; Reid AG; Deininger MW; Naresh K; Apperley JF; Khorashad JS
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638347
[TBL] [Abstract][Full Text] [Related]
18. Standard care and investigational drugs in the treatment of myelofibrosis.
Barraco D; Maffioli M; Passamonti F
Drugs Context; 2019; 8():212603. PubMed ID: 31645880
[TBL] [Abstract][Full Text] [Related]
19. Momelotinib for the treatment of myelofibrosis.
Bose P
Blood; 2024 Jul; ():. PubMed ID: 38958484
[TBL] [Abstract][Full Text] [Related]
20. The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms.
Bjørn ME; Hasselbalch HC
Clin Case Rep; 2015 Jun; 3(6):499-503. PubMed ID: 26185657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
